Evaluation of effect of acarbose consumption on weight losing in non-diabetic overweight or obese patients in Kerman

Journal of Research in Medical Sciences

Volumn 18, Issue 5, 2013, Pages 391-394

  Nakhaee, Akram ^a   Sanjari, Mojgan ^b  

^a KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Acarbose; Clinical trial; Non diabetics obese; Weight loss

Indexed keywords

ACARBOSE; LACTOSE; PLACEBO;

ABDOMINAL PAIN; ADULT; ARTICLE; BODY MASS; CARBOHYDRATE INTAKE; CHOLESTEROL BLOOD LEVEL; CLINICAL EVALUATION; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; EXERCISE; FEMALE; FLATULENCE; GLUCOSE BLOOD LEVEL; HUMAN; LOW CALORY DIET; MAJOR CLINICAL STUDY; MALE; NUTRITION; OBESITY; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION;

EID: 84879990788     PISSN: 17351995     EISSN: 17357136     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Fact sheet: Obesity and overweight. [Internet]. World Health Organization (WHO);2013 March. Avalilable from: http://www.who.int/mediacentre/factsheets/fs311/en.
2. Hadaegh F, Zabetian A, Tohidi M, Ghasemi A, Sheikholeslami F, Azizi F. Prevalence of metabolic syndrome by the Adult Treatment Panel III, International Diabetes Federation, and World Health Organization definitions and their association with coronary heart disease in an elderly Iranian population. Ann Acad Med Singapore 2009;38:142-9.
3. th ed. Philadelphia: WB Saunders; 2004. p. 860-99.
4. Kelishadi R, Ardalan G, Gheiratmand R, Gouya MM, Razaghi EM, Delavari A, et al. Association of physical activity and dietary behaviours in relation to the body mass index in a national sample of Iranian children and adolescents: CASPIAN Study. Bull World Health Organ 2007;85:19-26.
5. Lin BJ, Wu HP, Huang HS, Juang JH, Sison A, bin Abdul Kadir DK, et al. Efficacy and tolerability of acarbose in Asian patients with type 2 diabetes inadequately controlled with diet and sulfonylureas. J Diabetes Complications 2003;17:179-85.
6. Siraj ES. Is there a role for metformin or acarbose as a weight-loss agent in the absence of diabetes? Cleve Clin J Med 2003;70:702-4.
7. Bayraktar F, Hamulu F, Ozgen AG, Yilmaz C, Tüzün M, Kabalak T, et al. Acarbose treatment in obesity: A controlled study. Eat Weight Disord 1998;3:46-9.
8. Hauner H, Petzinna D, Sommerauer B, Toplak H. Effect of acarbose on weight maintenance after dietary weight loss in obese subjects. Diabetes Obes Metab 2001;3:423-7.
9. Wagner H, Degerblad M, Thorell A, Nygren J, Ståhle A, Kuhl J, et al. Combined treatment with exercise training and acarbose improves metabolic control and cardiovascular risk factor profile in subjects with mild type 2 diabetes. Diabetes Care 2006;29:1471-7.
10. Pan CY, Gao Y, Chen JW, Luo BY, Fu ZZ, Lu JM, et al. Efficacy of acarbose in Chinese subjects with impaired glucose tolerance. Diabetes Res Clin Pract 2003;61:183-90.
11. th ed. United States: Mc Graw Hill; 2005. p. 2380-5.
12. Wolever TM, Chiasson JL, Josse RG, Hunt JA, Palmason C, Rodger NW, et al. Small weight loss on long-term acarbose therapy with no change in dietary pattern or nutrient intake of individuals with non-insulin-dependent diabetes. Int J Obes Relat Metab Disord 1997;21:756-63.
13. Halpern A, Mancini MC, Suplicy H, Zanella MT, Repetto G, Gross J, et al. Latin-American trial of orlistat for weight loss and improvement in glycaemic profile in obese diabetic patients. Diabetes Obes Metab 2003;5:180-8.
14. Rachmani R, Bar-Dayan Y, Ronen Z, Levi Z, Slavachevsky I, Ravid M. The effect of acarbose on insulin resistance in obese hypertensive subjects with normal glucose tolerance: A randomized controlled study. Diabetes Obes Metab 2004;6:63-8.